ライフサイエンスコーパス: pericardial effusion

1 ation or PR depression, and new or worsening pericardial effusion).

2 tions of its treatment are a common cause of pericardial effusion.

3 aortic walls; aortic valve regurgitation; or pericardial effusion.

4 ight ventricular size, and the presence of a pericardial effusion.

5 No patient had a pericardial effusion.

6 raphic scan demonstrated a moderate to large pericardial effusion.

7 ve leaflets, and interatrial septum and mild pericardial effusion.

8 ed satisfactory device position and excluded pericardial effusion.

9 lar right atrial mass and moderate to severe pericardial effusion.

10 rdial rub, electrocardiographic changes, and pericardial effusion.

11 chest were obtained and indicated increasing pericardial effusion.

12 olated without steam pop, impedance rise, or pericardial effusion.

13 anized because of hypotension from a serious pericardial effusion.

14 icular dilation and dysfunction, and a large pericardial effusion.

15 more likely to have periaortic hematoma and pericardial effusion.

16 raphic changes and, at times, accompanied by pericardial effusion.

17 in cardiac enzyme elevation, perforation, or pericardial effusion.

18 patients with rupture or tamponade, 75% had pericardial effusions.

19 leviate high-volume and low-volume (<200 mL) pericardial effusions.

20 ally presented with hemothoraces rather than pericardial effusions.

21 II or III, right ventricular dysfunction and pericardial effusions.

22 l myocardial edema and fibrosis and frequent pericardial effusions.

23 sia, pleural effusions, chylothoraces and/or pericardial effusions.

24 e events included hemorrhage and pleural and pericardial effusions.

25 ications were device embolization (1.9%) and pericardial effusion (1.9%), with no cases of periproced

26 mplications occurred in 5 patients (0.4%): 2 pericardial effusions (1 intraoperative, 1 after 30 days

27 %], and 10 [0.4%], respectively; P>0.05) and pericardial effusion (11 [0.4%], 11 [0.8%], and 12 [0.5%

28 ronary syndromes (ACS) (1C), the presence of pericardial effusion (1C), cardiac tamponade (1B), valvu

29 , p < 0.001) along with higher incidences of pericardial effusion (20%, 0%, 0%, p < 0.001) and gastro

30 patient died following surgical drainage of pericardial effusion 3 weeks after the procedure.

31 sion (12%), reticular infiltration (4%), and pericardial effusion (4%).

32 ications included: generalized edema (5.5%), pericardial effusion (5.5%), facial edema (2.2%), and up

33 re echocardiography domains (adequate views, pericardial effusion, acute cor pulmonale, left ventricu

34 int: symptomatic cardiac events (symptomatic pericardial effusion, acute coronary syndrome, pericardi

35 prior sternotomy, there were no instances of pericardial effusion after extraction.

36 .9%) femoral artery dissection, and 3 (8.6%) pericardial effusions (all treated percutaneously).

37 ave confirmative diagnosis using a serology, pericardial effusion analysis or biopsy.

38 The poor survival among cancer patients with pericardial effusion and abnormal fluid cytology may hav

39 hemodynamic and echocardiographic variables, pericardial effusion and an enlarged right atrium remain

40 gainst fog1 resulted in embryos with a large pericardial effusion and an unlooped heart tube.

41 rsus 2.5%), largely related to more frequent pericardial effusion and device embolization.

42 cidence of acute severe pericarditis delayed pericardial effusion and gastrointestinal adverse effect

43 hanisms with a specific focus on the role of pericardial effusion and inflammation.

44 merging evidence suggests that postoperative pericardial effusion and localized pericardial inflammat

45 articularly strategies to reduce the risk of pericardial effusion and major bleeding, in women underg

46 t pain and epigastric pain was found to have pericardial effusion and pneumopericardium on computed i

47 higher risk of complications, predominantly pericardial effusion and procedural stroke related to ai

48 of Yap in Llgl1-depleted embryos ameliorated pericardial effusion and restored blood flow velocity.

49 lanted were observed to have higher rates of pericardial effusion and/or perforation but lower rates

50 Pericardial effusion and/or perforation within 30 days w

51 s reviewed as well as current treatments for pericardial effusions and constrictive pericarditis.

52 Pericardial effusions and myocardial fibrosis were 3 and

53 c AD but is more frequently complicated with pericardial effusions and periaortic hematoma.

54 polylobate, inhomogeneity, infiltration, and pericardial effusion) and mass tissue characterization f

55 not otherwise specified within 30 days, one pericardial effusion) and one in consolidation phase (es

56 embryonic day 10.5 and have thin ventricles, pericardial effusion, and a reduction in ventricular myo

57 mplications were shock, cardiac arrhythmias, pericardial effusion, and coronary artery dilatation.

58 clusive disease of lower extremities, pleuro-pericardial effusion, and debilitation.

59 endpoint for safety included major bleeding, pericardial effusion, and device embolisation.

60 creased aspartate aminotransferase, syncope, pericardial effusion, and hyperkalaemia, and grade 4 inc

61 sia, patent ductus arteriosus, cardiomegaly, pericardial effusion, and lymphoedema.

62 e rates of death, stroke, systemic embolism, pericardial effusion, and major bleeding were 5.8%, 1.9%

63 included appendicitis, spontaneous abortion, pericardial effusion, and seizure; none of the events oc

64 ension pneumothorax, drainage of pleural and pericardial effusions, and biliary drainage in cholangit

65 d growth retardation, marked bradycardia and pericardial effusions, and generalized edema, signs that

66 primary tool for diagnosing and quantifying pericardial effusions, and in the context of the clinica

67 onimmune hydrops fetalis (NIHF), pleural and pericardial effusions, and lymphedema.

68 b: acute renal failure; pleural effusion and pericardial effusion; and brain metastasis.

69 function, aortic or mitral valve disease, or pericardial effusion; and used transthoracic echocardiog

70 s, left ventricular systolic dysfunction and pericardial effusion are the most common cardiovascular

71 or bleeding, 9 had major bleeding, and 1 had pericardial effusion but no tamponade.

72 There were no pericardial effusions, but serious procedure/device-rela

73 mponade can be precipitated in patients with pericardial effusion by dehydration or exposure to certa

74 Pericardial effusions can be insidious, variable in pres

75 A retrospective review of pericardial effusion coincident with sirolimus therapy w

76 l accompanied by reduction of chest pain and pericardial effusion compared to baseline was demonstrat

77 Mild cardiac dysfunction and pericardial effusion developed, followed by acute respir

78 ce sizing and short-term outcomes, including pericardial effusion, device embolism, and significant l

79 h decompensated congestive heart failure and pericardial effusion diagnosed at echocardiography.

80 h decompensated congestive heart failure and pericardial effusion diagnosed on echocardiography.

81 cation, 2 for endoleak correction, and 2 for pericardial effusion drainage.

82 kg every 4 weeks plus tremelimumab 1 mg/kg), pericardial effusion (durvalumab 20 mg/kg every 4 weeks

83 ntricular size, and presence of a nontrivial pericardial effusion, expanding the reach of echocardiog

84 appearance, polylobate shape, infiltration, pericardial effusion, first-pass contrast perfusion, and

85 zing, there was no difference in the odds of pericardial effusion for either undersized (1.048 [95% C

86 The adverse reaction of pericardial effusion has been added to product labeling.

87 greater than 10 mm Hg among patients with a pericardial effusion helps distinguish those with cardia

88 , 1.777-6.584; P<0.001), and the presence of pericardial effusion (HR, 1.38; 95% confidence interval,

89 ted in larger and dysmorphic cardiomyocytes, pericardial effusion, impaired blood flow and aberrant v

90 occurred in 43 infants, cardiac arrest, and pericardial effusion in 17 infants, and noninfective thr

91 ity for left ventricular size, function, and pericardial effusion in 237 of 240 cases (98.8%) and rig

92 nction was reported in 484 patients (31.0%), pericardial effusion in 365 (23.4%), myocarditis in 300

93 nd spontaneous reports) contained reports of pericardial effusion in 56 sirolimus-treated patients, 3

94 n unusual case of massive pseudolymphomatous pericardial effusion in a cardiac transplant recipient.

95 We report here a rare case of pericardial effusion in a pediatric patient secondary to

96 Malignancy is the most common cause of pericardial effusion in a tertiary care center.

97 y revealed esophagopericardial fistulas with pericardial effusion in all patients, while contrast lea

98 tive model: p = 0.0161) were associated with pericardial effusion in females relative to healthy fema

99 ary-vein stenosis developed in two patients, pericardial effusion in one, and pulmonary edema in anot

100 nitial echocardiographic evaluation revealed pericardial effusions in 13 group A versus 4 group B fet

101 us greater than 10 mm Hg in a patient with a pericardial effusion increases the likelihood of tampona

102 Cancer-related pericardial effusion is associated with adverse outcomes

103 Pericardial effusion is common after cardiac surgery and

104 Although benign pericardial effusion is frequently seen in the post-card

105 The differential diagnosis of pericardial effusion is reviewed as well as current trea

106 am abnormalities, myocarditis, pericarditis, pericardial effusion, ischemic disease, and heart failur

107 is accompanied by hypotension and cyanosis, pericardial effusion, low voltage on the electrocardiogr

108 Malignant pericardial effusion may require emergency pericardiocen

109 evidence showing that reducing postoperative pericardial effusion might reduce POAF incidence.

110 = 1), left ventricular dysfunction (n = 1), pericardial effusion (n = 1), secondary bacterial or fun

111 pericarditis post-operatively (n = 2), late pericardial effusion (n = 1), unexplained sudden death (

112 dyspnoea (n=3 [5%]), pneumonitis (n=3 [5%]), pericardial effusion (n=2 [3%]), and upper respiratory i

113 ds), including pericardial tamponade (n=19), pericardial effusion (n=5), atrial perforation (n=3), J

114 f mortality included age, ejection fraction, pericardial effusion, N-terminal pro-B-type natriuretic

115 A pericardial effusion occurred in 1 patient: pericardioce

116 Significant pericardial effusion occurred in 16 patients (10.4%).

117 A significantly higher rate of pericardial effusion occurred with sirolimus versus azat

118 Although most of the pericardial effusions occurred in cardiac transplantatio

119 lications (device related access, stroke, or pericardial effusion) occurred in either group at follow

120 onfidence interval, 1.4-6.2; P<0.001), and a pericardial effusion (odds ratio, 2.5; 95% confidence in

121 cted carbon monoxide diffusing capacity, and pericardial effusion on echocardiogram all predicted mor

122 plications including one cardiac perforation/pericardial effusion, one nonocclusive femoral venous th

123 edural stroke without increasing the risk of pericardial effusion or other bleeding complications.

124 disability, be complicated by either a large pericardial effusion or tamponade, and carry a significa

125 spital death, myocardial infarction, stroke, pericardial effusion or tamponade, percutaneous coronary

126 No animal had pericardial effusion or tamponade.

127 rdiomyopathy, who also exhibit polycythemia, pericardial effusion, or goiter should be evaluated for

128 Pericardial effusion (p = 0.003) and indexed right atria

129 Pericardial effusion (p = 0.017), indexed right atrial a

130 Pericardial effusion (PE) is a potential complication of

131 Pericardial effusion (PE) is common in cancer patients,

132 Genotyping of cfDNA in pleural and pericardial effusion (PE-cfDNA) can further optimize mol

133 Four patients had bleeding complications (pericardial effusion, pericardial hematoma, hemoperitone

134 distress, along with weight gain, pleural or pericardial effusions, peripheral edema, thromboembolic

135 (%) value in samples of stable patients with pericardial effusions (PEs) (n = 94; 0.18% [0.07%-0.30%]

136 n, myocardial performance index, presence of pericardial effusion, pulmonary vascular resistance, car

137 Complications included one case of pericardial effusion related to venous mapping.

138 The natural history of pericardial effusion remains largely unknown.

139 2.06; 95% CI, 1.82-2.34; P < .001) owing to pericardial effusion requiring drainage (241 [1.2%] vs 1

140 nt (2%) in the rivaroxaban group developed a pericardial effusion requiring drainage, compared with n

141 patients; the most common complications were pericardial effusion requiring intervention (1.39%) and

142 cardia in 0.47%, heart failure in 0.47%, and pericardial effusion requiring intervention in 0.44%.

143 mic stroke in 0.23%, major bleeding in 3.1%, pericardial effusion requiring intervention in 0.50%, de

144 orted in 7 patients, no patients experienced pericardial effusion requiring open cardiac surgery, and

145 Pericardial effusions requiring surgical repair decrease

146 Pericardial effusions resolved and reappeared in both gr

147 ze and function, right ventricular size, and pericardial effusion, respectively.

148 Pericardial effusion, right atrial enlargement and septa

149 These data suggest that pericardial effusion should be considered in the differe

150 g, including mediastinal lymphadenopathy and pericardial effusion, showed no statistically significan

151 by the presence of fetal ascites, pleural or pericardial effusions, skin edema, cystic hygroma, incre

152 uded bleeding- and procedure-related events (pericardial effusion, stroke, device embolization).

153 Knockdown of emp2 in zebrafish resulted in pericardial effusion, supporting the pathogenic role of

154 The next most common complications were pericardial effusion/tamponade (0.78%) and stroke/transi

155 PR depression (~25%-50%); a new or increased pericardial effusion that is most often small (~60%); or

156 IPAH, after controlling for the presence of pericardial effusion; there was no significant change in

157 rformed safely in the absence of preexisting pericardial effusion to provide a novel route for cardia

158 dure-related complications included a single pericardial effusion treated with percutaneous drainage

159 and cardiogenic shock, 2 mild strokes, and a pericardial effusion treated with pericardiocentesis (n=

160 dyspnea, pulmonary infiltrates, pleural and pericardial effusions, unexplained fevers, hypotension,

161 eft and right ventricular size and function, pericardial effusion, valve morphology, and left atrial

162 ment of left ventricular function, ischemia, pericardial effusion, valvular disease, heart donor stat

163 ighly fatal adverse effect, pericarditis and pericardial effusions, vasculitis, thromboembolism, and

164 requiring immunosuppressant withdrawal, the pericardial effusion was a benign EBV-negative T cell pr

165 Cancer-related pericardial effusion was associated with decreased survi

166 A pericardial effusion was evident on fetal ultrasound in

167 The incidence of postoperative pericardial effusion was lower in the posterior left per

168 ity and only 1 hemodynamically insignificant pericardial effusion was observed at follow-up.

169 Pericardial effusion was observed in 123 patients (2.2%)

170 ion, severe valvular insufficiency and large pericardial effusion) was 99.0% (95% confidence interval

171 Cases of pericardial effusion were also observed in the sirolimus

172 Patients with cancer-related pericardial effusion were more likely to require repeat

173 Hypertension and pericardial effusion were not associated with decreased

174 Moderate and large pericardial effusion were uncommon with an incidence of

175 Pericardial effusions were common.

176 Pericardial effusions were excluded by serial echocardio

177 Compared with baseline, small pericardial effusions were more evident at follow-up (on

178 were observed in 29% of patients; pleural or pericardial effusions were observed in 1% (none were sev

179 h a history of chronic aortic dissection and pericardial effusion who was admitted to a teaching hosp

180 heart disease in HIV-1-infected patients are pericardial effusion with cardiac tamponade, high-grade

181 eeding, and 2 patients developed symptomatic pericardial effusion with need for pericardiocentesis 1

182 oped minor bleeding, and 1 patient developed pericardial effusion with no tamponade.

183 rt an unusual case of spontaneous Ureaplasma pericardial effusion with tamponade associated with pneu

184 s with preserved LVEF in 2, and an important pericardial effusion with tamponade in another.

185 Infectious pericardial effusion with tamponade is an uncommon but l

186 ere was a significantly higher rate of large pericardial effusions with LBN compared with MPN (8.1% v

187 The rate of serious pericardial effusion within 7 days of implantation, whic

188 tion, or kynurenine supplementation, lead to pericardial effusion, yolk sac edema, and excretion of h